MyoD1 Antibody (Immunohistochemistry)

The MyoD1 (Myogenic Differentiation 1) Antibody is a highly specific IHC marker.
It helps diagnose rhabdomyosarcoma and other tumors of myogenic origin.
In addition, MyoD1 is a 45 kDa nuclear transcription factor and a member of the
Myogenic Regulatory Factor (MRF) family, which also includes Myf5, Myf6, and Myogenin.

Moreover, MyoD1 plays a critical role in skeletal muscle differentiation and gene regulation.
As a result, strong nuclear positivity becomes a key diagnostic indicator for
alveolar and embryonal rhabdomyosarcoma.
Therefore, MyoD1 is an essential part of the diagnostic panel for muscle-derived tumors.

🔬 Features and Benefits

• Specific marker for skeletal muscle tumors such as rhabdomyosarcoma
• Clear brown nuclear staining in positive cells
• Helps distinguish myogenic from non-myogenic sarcomas
• Compatible with routine IHC protocols
• Stable for up to 18 months at 2–8 °C

💡 Diagnostic Applications

• Diagnosis of alveolar and embryonal rhabdomyosarcoma
• Differentiation between myogenic and non-myogenic sarcomas
• Research involving muscle differentiation and MRF gene regulation

🌐 Fardad Azma Rad Co.

Fardad Azma Rad Co., the exclusive representative of
Talent Biomedical in Iran, supplies premium-quality IHC antibodies such as MyoD1.
Furthermore, the company focuses on clinical accuracy, scientific reliability, and international diagnostic standards.
As a result, pathology laboratories and cancer research centers across Iran receive consistent and trusted support.

“Download Brochure”